PTC Therapeutics (PTCT) Gains as Sarepta's Eteplirsen Approved

September 19, 2016 9:54 AM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

PTC Therapeutics (NASDAQ: PTCT) gains as Sarepta's eteplirsen gains FDA accelerated approval.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Momentum Movers, Trader Talk

Add Your Comment